Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products

[1]  N. Pfeiffer,et al.  A 6-Month Study Comparing Efficacy , Safety , and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0 . 0015 % and Timolol 0 . 5 % versus Each of Its Individual Preservative-Free Components , 2014 .

[2]  F. Topouzis,et al.  Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice , 2014, Expert opinion on pharmacotherapy.

[3]  Taotao Ma,et al.  Flavonoids from Litsea coreana decreases TNF-α secretion from peritoneal macrophages in adjuvant-induced arthritis rats via UPR pathway. , 2014, The American journal of Chinese medicine.

[4]  G. Holló,et al.  Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. , 2014, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[5]  M. Kahook,et al.  24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost , 2014, Advances in Therapy.

[6]  I. Goldberg,et al.  Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial , 2014, British Journal of Ophthalmology.

[7]  Xinghuai Sun,et al.  Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open‐angle glaucoma or ocular hypertension , 2014, Chinese medical journal.

[8]  Y. Kitazawa,et al.  Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy , 2011, Eye.

[9]  S. Narumiya,et al.  International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress , 2011, Pharmacological Reviews.

[10]  R. Lewis,et al.  The Safety and Efficacy of Bimatoprost/Timolol Fixed Combination: A 1-year Double-masked, Randomized Parallel Comparison to Its Individual Components in Patients With Glaucoma or Ocular Hypertension , 2010, Journal of glaucoma.

[11]  A. Konstas,et al.  24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma , 2010, Eye.

[12]  Elizabeth E. Kim,et al.  A 12-Week, Randomized, Double-Masked Study of Fixed Combination Latanoprost/Timolol versus Latanoprost or Timolol Monotherapy , 2010, European journal of ophthalmology.

[13]  Elizabeth E. Kim,et al.  Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. , 2010, Archives of ophthalmology.

[14]  S. Miglior,et al.  Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension , 2009, Clinical ophthalmology.

[15]  M. Irkec,et al.  Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma , 2009, British Journal of Ophthalmology.

[16]  A. Konstas,et al.  Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open‐angle and exfoliative glaucoma , 2009, Acta ophthalmologica.

[17]  J. Brandt,et al.  Bimatoprost/Timolol Fixed Combination: A 3-month Double-masked, Randomized Parallel Comparison to Its Individual Components in Patients With Glaucoma or Ocular Hypertension , 2007, Journal of glaucoma.

[18]  Somani P.,et al.  Beta blockers? , 1970, Nature.

[19]  A. Robin,et al.  Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. , 2007, American journal of ophthalmology.

[20]  A. Robin.  A Double-Masked, Randomized, Parallel Comparison of a Fixed Combination of Bimatoprost 0.03%/Timolol 0.5% with Non-Fixed Combination Use in Patients with Glaucoma or Ocular Hypertension , 2007, European journal of ophthalmology.

[21]  S. Narumiya,et al.  The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice , 2007, British Journal of Ophthalmology.

[22]  F. Trimarchi,et al.  A 1-Year Study to Compare the Efficacy and Safety of Once-Daily Travoprost 0.004%/Timolol 0.5% to Once-Daily Latanoprost 0.005%/Timolol 0.5% in Patients with Open-Angle Glaucoma or Ocular Hypertension , 2007, European journal of ophthalmology.

[23]  G. Holló.  The side effects of the prostaglandin analogues , 2007, Expert opinion on drug safety.

[24]  J. Renard,et al.  A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. , 2006, Clinical therapeutics.

[25]  B. Svarstad,et al.  Patient-reported behavior and problems in using glaucoma medications. , 2006, Ophthalmology.

[26]  L. Larsson,et al.  A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. , 2005, Ophthalmology.

[27]  B. Hughes,et al.  A Three-Month, Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to Travoprost 0.004% Ophthalmic Solution and Timolol 0.5% Dosed Concomitantly in Subjects With Open Angle Glaucoma or Ocular Hypertension , 2005, Journal of glaucoma.

[28]  J. Schuman,et al.  Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. , 2005, American journal of ophthalmology.

[29]  John Samples,et al.  The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. , 2005, American journal of ophthalmology.

[30]  J. Meza,et al.  Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. , 2004, Ophthalmology.

[31]  T. Zimmerman,et al.  Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. , 2004, Clinical therapeutics.

[32]  M. Kageyama,et al.  Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. , 2004, Experimental eye research.

[33]  J. Crider,et al.  Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. , 2003, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[34]  L. Roberts,et al.  Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. , 2003, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[35]  N. Pfeiffer.  A comparison of the fixed combination of latanoprost and timolol with its individual components , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[36]  J. Johnson,et al.  The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. , 2002, Survey of ophthalmology.

[37]  L. Desantis,et al.  Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. , 2002, Survey of ophthalmology.

[38]  E. Higginbotham,et al.  Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. , 2002, Archives of ophthalmology.

[39]  R. Lai,et al.  The pharmacology of bimatoprost (Lumigan). , 2001, Survey of ophthalmology.

[40]  J. Stjernschantz,et al.  From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. , 2001, Investigative ophthalmology & visual science.

[41]  M. Astin.  A study on the vascular effects of prostaglandin F2α[ and latanaprost in the eye with special reference to the surface hyperaemia after topical administration , 1998 .

[42]  T. Zimmerman,et al.  Textbook of ocular pharmacology , 1997 .

[43]  G. Spaeth,et al.  Compliance in patients prescribed eyedrops for glaucoma. , 1995, Ophthalmic surgery.

[44]  M. Kass,et al.  Timolol maleate: efficacy and safety. , 1979, Archives of ophthalmology.

[45]  T. Zimmerman,et al.  Timolol: A β-Adrenergic Blocking Agent for the Treatment of Glaucoma , 1977 .